Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| FTH | 8-K | neutral | 2/10 | 🔒Faeth Therapeutics appointed Adam Schayowitz, Ph.D., as a Class III director, expanding the board from six to seven memb | Oct 27, 2026 |
| KNSA | 8-K | bullish | 6/10 | 🔒Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0M, up ~58% YoY, and raised full-year 2026 ARCALYST guidan | Oct 27, 2026 |
| KNSA | PRESS-RELEASE | bullish | 6/10 | 🔒Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0M, up ~58% YoY, and raised full-year 2026 ARCALYST revenu | Oct 27, 2026 |
| WVE | PRESS-RELEASE | neutral | 5/10 | 🔒Wave Life Sciences reported Q3 2026 revenue of $13.2M (up from $7.6M a year ago) and a net loss of $61.9M ($0.30 per sha | Oct 27, 2026 |
| CLRB | PRESS-RELEASE | bullish | 6/10 | 🔒Cellectar Biosciences reported a case study showing a durable complete response lasting over eight years in a heavily pr | Oct 27, 2026 |
| IPHA | 6-K | neutral | 4/10 | 🔒Innate Pharma announced that AstraZeneca has delayed the expected high-level data readout for the PACIFIC-9 Phase 3 tria | Oct 27, 2026 |
| PHAR | 6-K | bullish | 6/10 | 🔒Pharming Group reported strong Q3 2026 results with total revenue up 21% YoY to $117.6M, driven by 58% Joenja growth and | Oct 27, 2026 |
| IQV | 8-K | bullish | 6/10 | 🔒IQVIA reported Q3 2026 revenue of $4,428M (up 8.0% YoY) and adjusted diluted EPS of $3.34 (up 11.3% YoY), exceeding cons | Oct 27, 2026 |
| RGEN | 8-K | bullish | 6/10 | 🔒Repligen reported Q3 2026 revenue of $209.3M, up 11% YoY as reported and 12.5% organic, beating the $206.7M consensus. A | Oct 27, 2026 |
| RGEN | PRESS-RELEASE | bullish | 6/10 | 🔒Repligen reported Q3 2026 adjusted EPS of $0.53, beating the $0.46 consensus by 15.2%, and revenue of $209.3M, above the | Oct 27, 2026 |
| MSLE | 6-K | neutral | 2/10 | 🔒Satellos Bioscience announced the formation of a Scientific Advisory Board (SAB) with seven distinguished scientists in | Oct 27, 2026 |
| AZN | 6-K | bullish | 5/10 | 🔒AstraZeneca and Daiichi Sankyo's Enhertu received EU approval as adjuvant monotherapy for HER2-positive early breast can | Oct 27, 2026 |
| IMNN | S-1 | bearish | 6/10 | 🔒Imunon filed an S-1 registration for a best-efforts offering of up to 20M shares of common stock (or pre-funded warrants | Oct 27, 2026 |
| HCM | 6-K | neutral | 2/10 | 🔒HUTCHMED announced a November 5, 2026 expert webcast to discuss recent Phase III savolitinib data in MET-driven NSCLC, i | Oct 27, 2026 |
| NVS | 6-K | mixed | 6/10 | 🔒Novartis reported Q3 2026 net sales of USD 14.5 billion (+4% cc) and core operating income of USD 6.0 billion (+10% cc), | Oct 27, 2026 |
| PLUR | SC 13D/A | neutral | 5/10 | 🔒Chutzpah Holdings Ltd and affiliates (Alexandre Weinstein) filed Amendment No. 6 to their Schedule 13D, disclosing that | Oct 27, 2026 |
| ACRS | 8-K | bullish | 6/10 | 🔒Aclaris Therapeutics reported positive Phase 1b proof-of-concept primary analysis results for its anti-TSLP/IL-4R bispec | Oct 27, 2026 |
| IMNN | 8-K | neutral | 2/10 | 🔒Imunon filed an 8-K to announce that it made an investor presentation available for use in investor calls and conference | Oct 27, 2026 |
| ADIL | EFFECT | bearish | 6/10 | 🔒The SEC declared effective Adial Pharmaceuticals' S-3 registration statement (File No. 333-298636) on October 26, 2026. | Oct 27, 2026 |
| LNAI | EFFECT | bearish | 5/10 | 🔒The SEC declared effective Lunai Bioworks Inc.'s registration statement on Form S-1 (File No. 333-282898) under the 1933 | Oct 27, 2026 |
| ACTU | EFFECT | bearish | 6/10 | 🔒The SEC declared effective Actuate Therapeutics' S-1 registration statement (File No. 333-299332) on October 26, 2026, e | Oct 27, 2026 |
| INM | 425 | neutral | 3/10 | 🔒InMed announced the CVR distribution record date of November 5, 2026, for its proposed merger with Mentari Therapeutics. | Oct 27, 2026 |
| ACRS | PRESS-RELEASE | bullish | 7/10 | 🔒Aclaris Therapeutics announced positive Phase 1b proof-of-concept results for its bispecific antibody ATI-052 in atopic | Oct 27, 2026 |
| PHAR | PRESS-RELEASE | bullish | 6/10 | 🔒Pharming reported Q3 2026 total revenue of $117.6M, up 21% YoY and in line with the $117.6M consensus. GAAP diluted EPS | Oct 27, 2026 |
| HEPA | SC 13D | neutral | 5/10 | 🔒Gravitas Collective Corp. filed a Schedule 13D disclosing beneficial ownership of 25,000,000 shares of Hepion Pharmaceut | Oct 26, 2026 |
| JUNS | SC 13G/A | neutral | 2/10 | 🔒PharmAla Biotech Holdings Inc. filed an amendment to its Schedule 13G, confirming a 10.1% passive stake in Jupiter Neuro | Oct 26, 2026 |
| KRRO | INSIDER-BUY | bullish | 5/10 | 🔒Lynx1 Capital Management, a 10% owner of Korro Bio, purchased 12,175 shares at $9.68 for $118K in an open-market transac | Oct 26, 2026 |
| IRON | SC 13D/A | neutral | 3/10 | 🔒AI DMI LLC (Access Industries) filed Amendment No. 7 to its Schedule 13D for Disc Medicine, reporting a 6.6% beneficial | Oct 26, 2026 |
| KLRS | SC 13G | neutral | 3/10 | 🔒Coastlands Capital LP and related entities filed a Schedule 13G disclosing a 5.69% passive stake in Kalaris Therapeutics | Oct 26, 2026 |
| GRML | S-1 | neutral | 4/10 | 🔒Greenland Mines Ltd filed an S-1 registration statement to register 1,400,000 shares of common stock for resale by forme | Oct 26, 2026 |